Status:
COMPLETED
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety
Lead Sponsor:
S1 Biopharma, Inc.
Conditions:
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined)
Sexual Interest/Arousal Disorder (DSM-5 Defined)
Eligibility:
FEMALE
25-50 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to investigate whether Lorexys is effective and safe to treat premenopausal women who have lost their sexual desire to a distressing degree.
Detailed Description
Women are diagnosed with Hypoactive sexual desire disorder (HSDD) if they experience chronic loss of desire for sex together with significant distress or interpersonal difficulties due to this lack of...
Eligibility Criteria
Inclusion
- Age 25 to 50 and still having regular menstrual periods. Women with intact ovaries are classified as premenopausal for this study, even if they have had a hysterectomy. Women who have had both ovaries removed, even if under age 50 and with an intact uterus, are not acceptable for this study.
- In a stable, monogamous, communicative, reasonably amicable relationship for at least one year
- Meets DSM-IV-TR criteria for Generalized Acquired Hypoactive Sexual Desire Disorder and HSDD is her main sexual disorder
- Over the prior month, didn't respond to sexual initiations by partner
- At screen and baseline, low or no and infrequent or rare desire for sex
- At screen, has clinically relevant sexual distress as per FSDS-R score
- Otherwise healthy physically and mentally. Minor chronic conditions not affecting sexual function are allowed. Side effects from any continuing concomitant medications must be mild and stable or nil.
- Not pregnant or lactating for six months; using medically reliable contraception, i.e., diaphragm or (male or female) condom and spermicide, IUD, tubal sterilization, hormonal contraception (oral, vaginal, or implant), or (if the investigator finds the patient credibly monogamous) vasectomy of male partner.
- Gives informed consent for and is willing to undergo all of the scheduled evaluations
- Prompt for screening and baseline visits, is cooperative, and takes reasonable directions without excessive explanations
- Her sexual partner is in a monogamous relationship with her, is sexually unimpaired (erectile dysfunction allowed only if adequately treated), and is available to her at least half of the time (in days per week).
Exclusion
- Masturbates more than once a month.
- Sexual aversion or sexual pain disorder
- Chronic conditions that may reasonably be expected to be unstable or to affect sexual function (e.g., gastrointestinal bleeding, diabetes, frequent asthma, Major Depressive or anxiety disorder, history within the prior 6 months of suicidality or drug abuse; history of breast, cervical, uterine, ovarian or other systemic cancer).
- BMI (a standard ratio of weight to height) over 35.0 (obese)
- Requires CYP3A4, CYP 2B6, or CYP 2D6 strong inhibitor or inducer drugs
- Takes any sex hormone other than an approved hormonal contraceptive
- Takes an antiepileptic/mood stabilizer, antipsychotic, antidepressant, anti-anxiety, or hypnotic drug or has a history of allergic reaction to such drugs
- 9\. Drinks more than 7 alcoholic drinks per week (12-oz beer, 4-oz wine, 1 ½ oz liquor etc) 10. Drinks more than 6 cups of coffee or tea per day 11. History of seizures 12. Long QT syndrome (QTc \<=480 msec), other significant cardiovascular disease 13. moderate or severe dysfunction of the liver (any LFT \>=3x ULN) or renal dysfunction (BUN \> 30 or Cr \>2.0) 14. Uses sedating antihistamines or prescription sedatives 15. History of blood clots or abnormal bleeding tendencies, including daily use of medications adversely affecting coagulation, e.g., NSAIDs, systemic corticosteroids, or \>81 mg aspirin daily.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01857596
Start Date
April 1 2013
End Date
October 1 2014
Last Update
October 28 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert Taylor Segraves, MD, PhD
Beachwood, Ohio, United States, 44122
2
Molly Katz, MD
Cincinnati, Ohio, United States, 45219